REGENXBIO (RGNX) Competitors

Indivior (NASDAQ:INDV) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation.

Is INDV or RGNX more profitable?

Indivior has a net margin of -3.96% compared to REGENXBIO's net margin of -283.19%. REGENXBIO's return on equity of -70.65% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	-3.96%	-241.73%	15.09%
REGENXBIO	-283.19%	-70.65%	-41.68%

Does the MarketBeat Community prefer INDV or RGNX?

REGENXBIO received 432 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 65.44% of users gave REGENXBIO an outperform vote.

Company	Underperform	Outperform
Indivior	Outperform Votes 11 100.00%	Underperform Votes No Votes
REGENXBIO	Outperform Votes 443 65.44%	Underperform Votes 234 34.56%

Which has better valuation and earnings, INDV or RGNX?

Indivior has higher revenue and earnings than REGENXBIO. Indivior is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.17B	1.32	$2M	-$0.31	-36.23
REGENXBIO	$156.72M	3.12	-$263.49M	-$3.11	-3.13

Do institutionals and insiders believe in INDV or RGNX?

60.3% of Indivior shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 12.8% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media refer more to INDV or RGNX?

In the previous week, REGENXBIO had 26 more articles in the media than Indivior. MarketBeat recorded 29 mentions for REGENXBIO and 3 mentions for Indivior. Indivior's average media sentiment score of 1.68 beat REGENXBIO's score of 0.48 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
REGENXBIO	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, INDV or RGNX?

Indivior has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

Do analysts prefer INDV or RGNX?

Indivior presently has a consensus price target of $15.00, indicating a potential upside of 33.57%. REGENXBIO has a consensus price target of $31.63, indicating a potential upside of 224.93%. Given REGENXBIO's higher possible upside, analysts clearly believe REGENXBIO is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
REGENXBIO	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

REGENXBIO beats Indivior on 10 of the 19 factors compared between the two stocks.